The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
Recruitment status was Recruiting
To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia|
- To characterize the effects of sorafenib on specific molecular markers in patients with Barrett's esophagus and high grade intraepithelial neoplasia (HGIN) or carcinoma in situ (CIS). [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
- To determine the safety and feasibility of administering sorafenib to patients with Barrett's esophagus and HGIN or CIS. [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 2006|
|Estimated Study Completion Date:||May 2011|
|Estimated Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
2 tablets with water by mouth twice a day for two weeks.
Other Name: Sorafenib
To characterize the effects of sorafenib on specific molecular markers in patients with Barrett's esophagus and high grade intraepithelial neoplasia (HGIN) or carcinoma in situ (CIS).
|Contact: Ezra Cohen, MDfirstname.lastname@example.org|
|United States, Illinois|
|University of Chicago||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Ezra Cohen, MD 773-702-4137 email@example.com|
|Principal Investigator: Ezra Cohen, MD|
|Principal Investigator:||Ezra Cohen, MD||University of Chicago|